What's Happening?
Eli Lilly has decided to terminate its partnership with Rigel Pharmaceuticals, which focused on the development of RIPK1 inhibitors. This decision, effective June 15, will see Lilly returning the rights to two investigational RIPK1 inhibitors to Rigel and
ceasing any further milestone or payment obligations. The partnership, initiated in February 2021, involved a $125 million investment from Lilly, with Rigel eligible for up to $835 million in milestones. The collaboration aimed to develop drugs that regulate inflammation and cell death. However, progress has been limited, and Lilly had already discontinued a central nervous system program in October 2025. The remaining asset, ocadusertib, is currently in a mid-stage trial for rheumatoid arthritis, with the trial still recruiting participants. The broader RIPK1 drug development field has seen setbacks, with other major companies like Sanofi and Roche also discontinuing their RIPK1 programs due to unsatisfactory results.
Why It's Important?
The termination of the partnership between Eli Lilly and Rigel Pharmaceuticals highlights the challenges faced in the development of RIPK1 inhibitors, a drug class with potential applications in treating inflammatory and neurodegenerative diseases. This decision could have significant financial implications for Rigel, which must now reassess its strategy for the RIPK1 assets. The broader pharmaceutical industry has seen a trend of major players withdrawing from RIPK1 research, indicating potential difficulties in achieving clinical success with this modality. The impact on Rigel could be substantial, as the company loses a major partner and the associated financial support. This development may also influence investor confidence and future funding opportunities for similar biotech ventures.
What's Next?
Rigel Pharmaceuticals will regain full rights to the RIPK1 compounds and related programs after the partnership ends. The company will need to evaluate the financial and strategic implications of Lilly's withdrawal and decide on the future of the ocadusertib trial and other RIPK1 assets. The outcome of the ongoing rheumatoid arthritis trial will be crucial in determining the viability of continuing development independently or seeking new partnerships. The broader industry may see a shift in focus away from RIPK1 inhibitors unless new data or technological advancements can overcome the current challenges.
